We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+17.17%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.6B
AUM Growth
+$255M
Cap. Flow
-$1.97M
Cap. Flow %
-0.08%
Top 10 Hldgs %
27.03%
Holding
158
New
8
Increased
60
Reduced
24
Closed
11

Top Buys

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$19.4M
2
UNH icon
UnitedHealth
UNH
+$19.2M
3
WST icon
West Pharmaceutical
WST
+$14.7M
4
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$12.2M
5
ARGX icon
argenx
ARGX
+$11.5M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$41.1M
2
AET
Aetna Inc
AET
+$40.4M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$23.5M
4
PRAH
PRA Health Sciences, Inc.
PRAH
+$9.19M
5
ZTS icon
Zoetis
ZTS
+$8.44M

Sector Composition

Rank Sector Weight
1 Healthcare 89.28%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KURA icon
101
Kura Oncology
KURA
$850M
$7.28M 0.28%
400,000
+373,500
+1,409% +$6.33M
BLUE
102
DELISTED
bluebird bio
BLUE
$7.06M 0.27%
3,474
– –
ZLAB icon
103
Zai Lab
ZLAB
$2.62B
$6.97M 0.27%
300,000
+5,000
+2% +$108K
SYRE icon
104
Spyre Therapeutics
SYRE
$9.25B
$6.88M 0.26%
26,000
+5,036
+24% +$1.24M
GBT
105
DELISTED
Global Blood Therapeutics, Inc.
GBT
$6.78M 0.26%
150,000
– –
MYOV
106
DELISTED
Myovant Sciences Ltd.
MYOV
$6.75M 0.26%
295,100
– –
RYTM icon
107
Rhythm Pharmaceuticals
RYTM
$7.96B
$6.72M 0.26%
215,000
+143,500
+201% +$3.92M
ACHN
108
DELISTED
Achillion Pharmaceuticals
ACHN
$6.65M 0.26%
2,350,000
+100,000
+4% +$341K
LJPC
109
DELISTED
La Jolla Pharmaceutical Company
LJPC
$6.48M 0.25%
222,300
+2,300
+1% +$71K
CRVS icon
110
Corvus Pharmaceuticals
CRVS
$1.17B
$6.31M 0.24%
575,000
– –
MGNX icon
111
MacroGenics
MGNX
$257M
$5.68M 0.22%
275,000
– –
BSX icon
112
Boston Scientific
BSX
$71.5B
$5.64M 0.22%
+172,500
New +$5.2M
DERM
113
DELISTED
Dermira, Inc.
DERM
$5.52M 0.21%
600,000
– –
ONCT
114
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$5.42M 0.21%
2,529
– –
EVHC
115
DELISTED
Envision Healthcare Holdings Inc
EVHC
$4.85M 0.19%
+110,300
New +$4.53M
ADVM
116
DELISTED
Adverum Biotechnologies
ADVM
$4.77M 0.18%
90,000
– –
PRTK
117
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$4.59M 0.18%
450,000
– –
CMTA
118
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$4.54M 0.17%
345,000
– –
CORV
119
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$4.54M 0.17%
1,200,000
– –
NVAX icon
120
Novavax
NVAX
$1.31B
$4.36M 0.17%
162,500
+25,000
+18% +$845K
DVAX
121
DELISTED
Dynavax Technologies
DVAX
$4.09M 0.16%
268,000
+17,000
+7% +$294K
CGEN icon
122
Compugen
CGEN
$228M
$3.56M 0.14%
1,078,165
+253,165
+31% +$952K
SLDB icon
123
Solid Biosciences
SLDB
$900M
$3.38M 0.13%
6,333
-2,000
-24% -$615K
ITCI
124
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.31M 0.13%
187,500
– –
AGN
125
DELISTED
Allergan plc
AGN
$2.94M 0.11%
17,665
– –
2 3 4
5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Rock Springs Capital Management held 158 positions worth $2.6B, up 11% from $2.34B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management's Q2 2018 filing shows 8 new, 60 increased, 24 reduced and 11 closed positions. Its largest new stake was West Pharmaceutical: 160,000 shares worth $15.9M. The largest sale was Bristol-Myers Squibb, an estimated $41.1M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 88% a quarter earlier, followed by Financials.

  • Rock Springs Capital Management's largest Q2 2018 buy was West Pharmaceutical: 160,000 shares worth $15.9M.
  • Rock Springs Capital Management added most to Wellcare Health Plans, Inc. in Q2 2018, an estimated $19.4M increase.
  • Rock Springs Capital Management's biggest Q2 2018 reduction was PRA Health Sciences, Inc., cutting an estimated $9.19M.
  • Rock Springs Capital Management fully exited Bristol-Myers Squibb in Q2 2018, selling an estimated $41.1M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $2.6B portfolio in Q2 2018.
  • Rock Springs Capital Management opened 8 new positions and closed 11 in Q2 2018.
  • Rock Springs Capital Management's portfolio value rose 11% quarter-over-quarter to $2.6B.

Based on Rock Springs Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.